UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the outcome of today's meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which discussed the new drug application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. By a narrow margin, the ODAC voted 4 to 5 that the benefit/risk of UGN-102 (mitomycin) for intravesical solution was favorable for the treatment of recurrent LG-IR-NMIBC.
'While we are disappointed by today's outcome, we continue to believe our clinical data support UGN-102 for the treatment of recurrent LG-IR-NMIBC, a disease with no FDA-approved therapies,' said Liz Barrett, President and CEO of UroGen. 'The FDA carefully considers the independent advice from ODAC, and we look forward to working with the FDA as they complete their review of the application for UGN-102.'
The ODAC reviewed the body of clinical data supporting the efficacy and safety of UGN-102, including the results from the Phase 3 ENVISION study. 'Low-grade intermediate-risk non-muscle invasive bladder cancer is a highly recurrent disease and often requires patients – many of whom are elderly – to undergo repeat surgeries under general anesthesia. This is a disease with high unmet needs, and we believe patients deserve more options,' said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. 'UroGen remains committed to developing innovative treatment options to people living with recurrent LG-IR-NIMBC.'
The most common treatment-emergent adverse events in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention, which are typically manageable in routine urologic practice. The ENVISION trial demonstrated a similar safety profile to that observed in other studies of UGN-102.
The NDA for UGN-102 is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of June 13, 2025.
About UGN-102
UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel ® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the submission of the rolling NDA for UGN-102 in August 2024, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA target action date of June 13, 2025.
About Non-Muscle Invasive Bladder Cancer (NMIBC)
LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at www.BladderCancerAnswers.com.
About ENVISION
The Phase 3 ENVISION trial is a single-arm, multinational, multicenter pivotal study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as a chemoablative therapy in patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at three months after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 as the first and only FDA-approved treatment for recurrent LG-IR-NMIBC; statements related to UroGen's UGN-102 NDA and expected PDUFA target action date; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential patient benefits and opportunities for UGN-102, if approved; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as 'expect,' 'if,' 'potential,' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary results may not be indicative of results that may be observed in the future; the ability to obtain regulatory approval within the timeframe expected, or at all; although the FDA is not bound by the ODAC's recommendation, the recommendation may adversely impact the FDA's decision on the NDA for UGN-102; the PDUFA target action date may be delayed due to various factors outside UroGen's control; the ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; the ability to obtain and maintain regulatory approval within the timeframe expected, or at all; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's product and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; UroGen's RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025. The events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Salmonella recall of 20 million eggs from Walmart, Safeway, Ralphs, among others
Another salmonella outbreak caused the recall of 1.7 million dozen eggs — meaning roughly more than 20 million less eggs to fry — and has sickened people in seven states. The aforementioned eggs were distributed to Walmart, Safeway, chains owned by Kroger and various other independent and chain supermarkets. Hilmar, California's August Egg Company, a division of Gemperle Enterprises, produced the eggs and issued the recall Friday. 'August Egg Company is not selling fresh shell eggs at this time,' the company-written, FDA-posted recall notice said. 'Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens.' READ MORE: Public health alert: Deadly E. coli found in beef sent to Whole Foods stores What eggs have been recalled? Packaging for the recalled eggs will have plant code P-6562 or CA5330 with the Julian Dates between 32 to 126. The eggs that went to Walmart stores had sell by dates from March 4 through June 19. Other retailers got eggs with 'sell by dates' from March 4 through June 4. August Egg says these eggs went to stores in California, Washington, Illinois, Nevada, Arizona, Wyoming, New Mexico, Nebraska, and Indiana. The recall section of Walmart's website says this also involves its stores in Alaska, Colorado, Hawaii, Iowa, Idaho, Kansas, Michigan, Montana, North Dakota, Ohio, Oklahoma, Oregon, Texas and Wisconsin. ▪ Marketside (a Walmart store brand): Organic Large Cage Free Brown Eggs in cartons of 12 and 18; Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ First Street (a Smart & Final house brand): Cage Free Large Brown loose eggs. ▪ Clover: Organic Large Brown Eggs, one dozen. ▪ Nulaid: One dozen Medium Brown Cage Free, one dozen Jumbo Brown Cage Free. ▪ O Organics: Cage Free Large Brown, six eggs; and Large Brown, 12 and 18 eggs. This brand will be found at Safeway and other Albertson's-owned stores. ▪ Raley's (store brand): Large Cage Free Brown, 12 eggs: Organic Large Cage Free Brown, 12 and 18 eggs. ▪ Simple Truth: Cage Free Large Brown and Medium Brown 18 eggs. This brand will be found at Food 4 Less, Ralphs and other Kroger-owned chains. ▪ Sun Harvest: Organic Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ Sunnyside: Organic Large Cage Free Brown Eggs in cartons of 12 and 18; and Large Cage Free Brown Eggs in cartons of 12 and 18. What's up with the salmonella outbreak? Saturday's outbreak update from the Centers for Disease Control and Prevention says 79 people have been sickened in this outbreak with 21 hospitalizations. Of those 79, 63 are in California. The remaining 16 break down as Nevada and Washington (four each); Arizona, three; Nebraska and New Jersey (two each); and Kentucky, one. Salmonella outbreaks tend to be very undercounted because most people recover without medical attention. What is salmonella? The CDC estimates about 1.35 million people in the United States will get salmonella each year. Of that number, 26,400 will be hospitalized, usually driven to the hospital by bloody diarrhea, and 420 will die. Usually, salmonella just means a few days of diarrhea, vomiting, fever and stomachaches. What you should do now If you have any of the recalled eggs listed above, return them to the store for a refund or throw them deep into the garbage. If you have any questions about the recalls, call August Farms at 800-710-2554, noon to 8 p.m., Eastern time.
Yahoo
4 hours ago
- Yahoo
These Popular Eggs Are Being Recalled Over Salmonella Risk
If you've been living for your morning sunny-side eggs…well, brace yourself. The August Egg Company—the parent behind Sunnyside, Clover, Raley's, and a few other brands—is recalling a whopping 1.7 million dozen eggs due to a potential salmonella outbreak. Yep, it's serious.. The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention have flagged the August Company's 'brown cage-free and brown certified organic egg' for possible contamination, meaning you might want to double-check that carton in your fridge before cracking it open. If you didn't know, Salmonella is that sneaky bacteria behind food poisoning and can cause anything from mild stomach upset to serious illness. These eggs were shipped to Walmart stores and other grocers in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. They have a best-by date from March 4 to June 19 and food codes P-6562 or CA5330. Not sure if your eggs are on the list? The FDA has a full rundown of all the recalled brands you can check out. And if the cartons in your fridge match any of the food codes or best-by-dates, toss them out immediately. While it's somewhat okay to eat an egg past its expiration date, this isn't the case. The FDA has already connected a current salmonella outbreak to the eggs. As of now, a total of 79 cases have been reported in seven states, while 21 people have been hospitalized. We get it: eggs are pricey, and tossing them feels like a waste. But don't risk it. Plus, most places will give you a full refund. And if your eggs touched any surfaces, wipe those down like your life depends on it. If after eating you feel dizzy, nauseous, or get a fever—don't play it cool. Call your doctor. This is serious business. Trust me, as a four-time survivor of food poisoning, you don't want to take any chances. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
6 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
